Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies

J Crohns Colitis. 2017 Jan;11(1):1-2. doi: 10.1093/ecco-jcc/jjw141. Epub 2016 Jul 31.

Authors

Iris Detrez¹, Ann Gils²

Affiliations

¹ Department of Pharmaceutical and Pharmacological Sciences, Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven, Leuven, Belgium.
² Department of Pharmaceutical and Pharmacological Sciences, Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven, Leuven, Belgium ann.gils@pharm.kuleuven.be.

PMID: 27481879
DOI: 10.1093/ecco-jcc/jjw141

No abstract available

Publication types

Clinical Trial, Phase II
Clinical Trial, Phase III
Editorial

MeSH terms

Antibodies, Monoclonal / pharmacokinetics
Antibodies, Monoclonal / therapeutic use*
Colitis, Ulcerative / drug therapy*
Humans
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

Antibodies, Monoclonal
Tumor Necrosis Factor-alpha
golimumab